Mural Oncology plc (NASDAQ:MURA) Short Interest Update

Mural Oncology plc (NASDAQ:MURA) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 594,500 shares, a growth of 46.4% from the March 15th total of 406,100 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average daily trading volume, of 278,000 shares, the days-to-cover ratio is currently 2.1 days.

Analysts Set New Price Targets

Several research analysts have recently weighed in on MURA shares. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research note on Tuesday, March 25th. Morgan Stanley lowered shares of Mural Oncology from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, March 25th. Raymond James cut shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price on the stock. in a report on Tuesday, March 25th. Finally, HC Wainwright cut their price target on Mural Oncology from $18.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Hedge Funds Weigh In On Mural Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC lifted its holdings in shares of Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after acquiring an additional 11,423 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Mural Oncology during the 4th quarter valued at about $68,000. Two Sigma Advisers LP purchased a new stake in Mural Oncology in the fourth quarter worth approximately $84,000. Bridgeway Capital Management LLC bought a new position in Mural Oncology during the fourth quarter valued at approximately $94,000. Finally, Northern Trust Corp raised its stake in shares of Mural Oncology by 22.0% during the fourth quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after acquiring an additional 7,197 shares in the last quarter. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Price Performance

NASDAQ:MURA traded up $0.28 during trading hours on Friday, hitting $2.70. The stock had a trading volume of 5,740,612 shares, compared to its average volume of 1,273,559. The company has a 50 day simple moving average of $2.89 and a two-hundred day simple moving average of $3.37. The firm has a market capitalization of $46.52 million, a price-to-earnings ratio of -0.30 and a beta of 5.28. Mural Oncology has a one year low of $0.95 and a one year high of $4.74.

Mural Oncology (NASDAQ:MURA) last announced its earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period last year, the company posted ($3.57) earnings per share. Equities research analysts anticipate that Mural Oncology will post -7.54 earnings per share for the current year.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.